Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • IL Receptor
    (8)
  • JAK
    (6)
  • Interleukin
    (4)
  • PDE
    (4)
  • Histamine Receptor
    (3)
  • STAT
    (3)
  • Endogenous Metabolite
    (2)
  • Glucocorticoid Receptor
    (2)
  • Immunology/Inflammation related
    (2)
  • Others
    (21)
Filter
Search Result
Results for "

atopic

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    80
    TargetMol | Inhibitors_Agonists
  • Compound Libraries
    1
    TargetMol | Compound_Libraries
  • Inhibitory Antibodies
    21
    TargetMol | Inhibitory_Antibodies
  • Natural Products
    5
    TargetMol | Natural_Products
  • Recombinant Protein
    6
    TargetMol | Recombinant_Protein
  • Isotope Products
    1
    TargetMol | Isotope_Products
  • Disease Modeling
    1
    TargetMol | Disease_Modeling_Products
  • Cell Research
    4
    TargetMol | Inhibitors_Agonists
Difamilast
T27172937782-05-3
Difamilast is an inhibitor of phosphodiesterase IV.
  • $63
In Stock
Size
QTY
Dupilumab
SAR-231893, REGN-668
T136661190264-60-8
Dupilumab (REGN-668) is a fully human monoclonal antibody targeting the alpha subunit of the interleukin-4 receptor, thereby inhibiting IL-4 and IL-13 signaling. As a systemic immunomodulator, it has demonstrated efficacy in improving atopic dermatitis.
  • $239
In Stock
Size
QTY
TargetMol | Inhibitor Hot
Oxazolone
4-Ethoxymethylene-2-phenyl-2-oxazolin-5-one
T509515646-46-5
Oxazolone is a haptenating agent that can induce models of acute or chronic colitis and atopic dermatitis. It activates Th1 Th2 responses, leading to weight loss and diarrhea, and the resulting inflammation can be alleviated by anti-IL-4 antibodies, anti-TNF-α antibodies, or IL-13R2α-Fc fusion proteins. It is also suitable for studying gene expression related to inflammatory bowel disease in zebrafish.
  • $29
In Stock
Size
QTY
TargetMol | Inhibitor Hot
Vapitadine
R 129160
T29096L793655-64-8In house
Vapitadine is a non-sedative antihistamine compound that relieves itching caused by atopic dermatitis.
  • $195
In Stock
Size
QTY
PF-07038124 HCl
PF-07038124 HCl(2415085-44-6 Free base)
T60921L2415317-57-4In house
PF-07038124 HCl is a selective and potent PDE4 inhibitor with an IC50 of 0.5 nM for PDE4B2.PF-07038124 HCl inhibits IL-13, IL-4, and IFNγ, and can be used in the study of skin disorders such as atopic dermatitis and plaque psoriasis.
  • $195 TargetMol
In Stock
Size
QTY
GLPG2534
GLPG-2534
T751132095615-97-5In house
GLPG2534 is an orally active, selective and potent IRAK4 inhibitor with anti-inflammatory activity. GLPG2534 inhibits human and mouse IRAK4 and could be used to study psoriasis and atopic dermatitis.
  • $113
In Stock
Size
QTY
Clobetasone butyrate
T1498125122-57-0
Clobetasone butyrate, a synthetic glucocorticoid with topical anti-inflammatory activity, is effective in treating corticosteroid-responsive dermatoses, such as atopic dermatitis and psoriasis, especially within skin tissues.
  • $37
In Stock
Size
QTY
Trans-Tranilast
Tranilast trans-
T227070806-55-2
Trans-Tranilast is an antiallergic drug developed by Kissei Pharmaceuticals. It was approved in 1982 for use in Japan and South Korea for bronchial asthma. Indications for keloid and hypertrophic scar were added in 1993. It has been used for the treatment of allergic disorders such as asthma, allergic rhinitis and atopic dermatitis.
  • $32
In Stock
Size
QTY
Nafamostat mesylate
FUT-175
T239282956-11-4
Nafamostat mesylate (FUT-175), a synthetic serine protease inhibitor, has been used for the treatment of allergic disorders such as asthma, allergic rhinitis and atopic dermatitis.
  • $39
In Stock
Size
QTY
Tranilast
SB 252218, MK 341
T269053902-12-8
Tranilast (SB 252218), an antiallergic drug, suppresses lipid mediator and cytokine release from inflammatory cells, therefore utilized in the treatment of allergic disorders.
  • $36
In Stock
Size
QTY
Ufenamate
Flufenamic acid butyl ester, Butyl flufenamate
T496667330-25-0
Ufenamate (Flufenamic acid butyl ester) is an anthranilic acid-based anti-inflammatory drug developed for the treatment of skin diseases.
  • $31
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Bepotastine Besilate
TAU 284, Talion, Bepreve, Bepotastine Beslilate
T6405190786-44-8
Bepotastine Besilate (TAU 284) is a non-sedating and selective H1 receptor antagonist (pIC50: 5.7).
  • $39
In Stock
Size
QTY
Rovazolac
ALX-101
T167921454288-88-0
Rovazolac (ALX-101) is a liver x receptor (LXR) modulator used in the study of immune system disorders and atopic dermatitis.
  • $74
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Mapracorat
ZK-245186, ZK245186, BOL-303242X, BOL303242X
T13451L887375-26-0
Mapracorat (ZK-245186, BOL-303242X) is a selective glucocorticoid receptor agonist commonly used as an anti-inflammatory agent for atopic dermatitis, post-cataract surgery inflammation, and allergic conjunctivitis.
    7-10 days
    Inquiry
    Alclometasone
    7a-​Chloro-​16a-​methyl prednisolone
    T1415467452-97-5
    Alclometasone (7a-Chloro-16a-methyl prednisolone), a glucocorticoid, inhibits leukocyte release of pro-inflammatory mediators and effectively treats corticosteroid-responsive dermatoses such as atopic dermatitis, psoriasis, allergic dermatitis, and eczema [1].
    • $2,720
    3-6 months
    Size
    QTY
    Asivatrep
    PAC-14028, PAC14028
    T164261005168-10-4
    Asivatrep (PAC14028) is a selective and potent antagonist of transient receptor potential vanilloid subtype 1 (TRPV1) for the study of atopic dermatitis.
    • $347
    6-8 weeks
    Size
    QTY
    PQA-18
    Prenylated Quinolinecarboxylic Acid Compound-18
    T2013601604678-82-1
    PQA-18, an inhibitor of p21-activated kinase 2 (PAK2; IC50 = 10 nM), is derived from Ppc-1 (product number 42352) and exhibits immunosuppressive properties. It inhibits IL-2 production in Jurkat T cells induced by Concanavalin A (product number 14951) with an IC50 of 400 nM. Topically applied at 0.1%, PQA-18 reduces the severity of atopic dermatitis, serum IgE levels, and skin thickness in the NC Nga mouse model. A lower concentration of 0.05% also decreases skin nerve fiber density in NC Nga mice. Additionally, PQA-18 administered at 4 mg kg improves graft survival in a rat small intestine transplantation model.
    • $1,620
    2-4 weeks
    Size
    QTY
    Sudexanox
    T20210458761-87-8
    Sudexanox, a flavonoid derivative, is utilized in the treatment of allergies, atopic asthma, and asthmatic bronchitis. In preclinical studies, Sudexanox has demonstrated potent activity in an IgE-induced passive cutaneous anaphylaxis model in rats.
    • Inquiry Price
    10-14 weeks
    Size
    QTY
    KRO-105714
    KRO105714, KRO 105714
    T2028241137536-21-0
    KRO-105714 is a novel SPC and S1P1 antagonist that has been shown to alleviate symptoms of atopic dermatitis in various mouse models.
    • Inquiry Price
    10-14 weeks
    Size
    QTY
    CEE321
    T2048242098545-89-0
    CEE321 is an effective pan-JAK inhibitor with an IC50 of 54 nM. It effectively inhibits biomarkers associated with atopic dermatitis.
    • Inquiry Price
    10-14 weeks
    Size
    QTY
    JAK1/STAT3-IN-1
    T205385
    JAK1 STAT3-IN-1 (compound 4f) functions as an anti-atopic dermatitis (AD) agent by inhibiting the JAK1 STAT3 signaling pathway. It has an IC50 value of 2.17 μM for inhibiting NO production. Additionally, JAK1 STAT3-IN-1 improves skin conditions in AD-like mice by reducing inflammatory infiltration, suppressing the expression of p-JAK1 JAK1 and p-STAT3 STAT3, and alleviating the hyperimmune response induced by MC903 (Calcipotriol).
    • Inquiry Price
    Size
    QTY
    LNK01004
    T2053872445500-24-1
    LNK01004 is a JAK inhibitor that exhibits potent inhibitory effects on JAK1 (IC50: 10 nM), JAK2 (IC50: <0.51 nM), and TYK2 (IC50: 1.0 nM). It can concurrently inhibit multiple cytokine-induced p-STAT signaling pathways and is applicable for research on diseases such as atopic dermatitis.
    • Inquiry Price
    10-14 weeks
    Size
    QTY
    PARP14 inhibitor 1
    T2068183035493-13-8
    PARP14 inhibitor1 (compound Q22) is a selective inhibitor of PARP14 with an IC50 of 5.52 nM. It also exhibits anti-inflammatory properties and has a half-life of 182 minutes in mouse liver microsomes. This compound is applicable for atopic dermatitis research.
    • Inquiry Price
    10-14 weeks
    Size
    QTY
    HDAC6-IN-55
    T206919
    HDAC6-IN-55 (Compound 15B) is a potent HDAC6 inhibitor and an effective anti-inflammatory agent. It mitigates inflammation through the TLR4/MAPK, STAT3, and NF-κB pathways, providing relief from atopic dermatitis. HDAC6-IN-55 alleviates symptoms such as skin edema, dryness, crusting, and peeling in mice with atopic dermatitis induced by 2,4-dinitrochlorobenzene (DNCB).
    • Inquiry Price
    Size
    QTY